Oliver Mobasser is an associate in the London office. Mr. Mobasser has particular expertise in the healthcare and life sciences sectors, advising multinational pharmaceutical, biotechnology and medical technology companies and their investors on complex licenses, collaborations, acquisitions, divestments, commercial contracts, intellectual property matters, and regulatory and privacy matters.

Prior to joining Latham, Mr. Mobasser was a solicitor at a leading firm in Dublin, Ireland, as well as completing a secondment as in-house counsel for Shire Pharmaceuticals in 2017/2018. 

Mr. Mobasser’s experience covers: 

  • Product licensing and acquisitions 
  • Complex commercial contracts and collaborations 
  • Technology and life sciences transactions
  • Business carve out transactions 
  • Digital health
  • Data protection 

Mr. Mobasser’s representative experience includes advising: 

  • GSK on a variety of matters, including: 
    • Its strategic global collaboration and licensing agreement with Alector for the development and commercialization of two clinical-stage, potential first-in-class monoclonal antibodies for a range of neurodegenerative diseases, including frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson’s disease and Alzheimer’s disease
    • Its global license and collaboration with SpringWorks Therapeutics, Inc. for development and commercialization of nirogacestat, SpringWorks’ investigational oral gamma secretase inhibitor, in combination with Blenrep (belantamab mafodotin-blmf), GSK’s antibody-drug conjugate targeting B-cell maturation antigen (BCMA) 
    • Various other early-stage clinical trial, collaboration, development, and supply arrangements 
    • The divestment of its Prevacid 24HR business to Perrigo Company 
    • The divestment of assets relating to the Bialcol and Cibalgina brands in Italy to Vemedia 
    • The divestment of five over-the-counter dermatology brands and one pediatric cough remedy brand to the STADA Group 
    • The divestment of four established over-the-counter brands in eight countries to Pharma SGP
  • Swedish Orphan Biovitrum AB (publ) (Sobi™) on a variety of matters, including:
    • Its strategic licensing agreement with Selecta Biosciences for SEL-212, a phase-3 ready therapy for the treatment of chronic refractory gout, with a deal value of approximately US$730 million 
    • Its strategic licensing and collaboration agreement with Apellis Pharmaceuticals Inc. for co-development and exclusive ex-US commercialisation rights for systemic pegcetacoplan
  • Norgine, a Netherlands-based specialty pharmaceutical company, in its US$2 billion sale to Goldman Sachs
  • Theramex, a global specialty pharmaceutical company dedicated to women’s healthcare, in connection with its its licensing agreement with ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies for women’s health, to commercialise and launch Linzagolix, an oral GnRH antagonist 
  • Astorg and OPEN Health, on data protection matters related to the acquisition of The CM Group, an integrated commercialization platform 
  • Lindsay Goldberg, on data protection matters related to its investment in MMS Holdings Inc., a leading data-focused contract research organization
  • Leadiant Biosciences on the sale of all of its assets relating to Revcovi, a pharmaceutical product for the treatment of a rare immunodeficiency disease, to Chiesi Farmaceutici
  • Novo Holdings A/S on its acquisition of BBI Group, a leading supplier of products and services to the global diagnostics and life sciences industries
  • A consortium consisting of Astorg Asset Management, Nordic Capital, Novo Holdings and their portfolio company eResearchTechnologies on the data privacy aspects of its merger with Bioclinica, a technological and scientific leader in clinical imaging
  • Frontier Medicines, Corp. on the data privacy aspects of its global partnership with AbbVie to discover, develop and commercialize a pipeline of innovative small molecule therapeutics against high-interest, difficult-to-drug protein target
  • Acino Pharma in relation to its purchase of a portfolio of over-the-counter and prescription pharmaceutical products in the Near East, Middle East and Africa, for a total value in excess of US$200 million 
  • Oasmia Pharmaceutical AB on its global strategic partnership for the development and commercialization of its proprietary anticancer product Apealea with Elevar Therapeutics, with a deal value of approximately USD$698 million 
  • Ligand Pharmaceuticals on its sale of Vernalis (R&D) Limited, a UK-based fragment and structure-based drug discovery research company, to HitGen
  • Permira, on contracts, regulatory and IP matters related the joint acquisition and combination of Kedrion Biopharma and Bio Products Laboratory, two leading providers of medicinal products derived from human blood plasma
  • Permira on data protection, contracts, regulatory and IP matters related to the acquisition of Quotient Sciences, a provider of CDMO and CRO services to pharma and biotech companies 
  • Quotient Sciences on its acquisition of Arcinova, the UK based multiservice contract development and manufacturing organization 
  • BC Partners on IP, contracts, data protection and regulatory matters related to the acquisition of a majority interest in Synthon International Holding B.V., a global market leader in the development of complex generics 
  • Various pharmaceutical and medical technology companies on agreements for the conduct of clinical trials in the EU, including GDPR compliance aspects of such trials

*Matter handled prior to joining Latham & Watkins 

Bar Qualification

  • England and Wales (Solicitor)


  • BCL in Law & Philosophy, University College Dublin, 2012
    First Class